PALISI Approved Survey: Hospital and Provider Utilization of Methylene Blue in Pediatric Septic Shock
Calling Pediatric Critical Care Physicians, PNPs, or Fellows: We Want to Hear From You!
Methylene blue is increasingly considered an adjunctive therapy for catecholamine-refractory or vasoplegic pediatric septic shock. However, limited pediatric evidence and variability in clinical practice make it difficult to establish consensus regarding its use.
My name is Stacey Sears, and I am a Pediatric Acute Care Nurse Practitioner in the PICU at C.S. Mott Children’s Hospital. For my PhD dissertation, I am conducting a national survey of pediatric critical care clinicians to examine current practices, indications, perceived effectiveness, and barriers to using methylene blue in critically ill children (Hospital and Provider Utilization of Methylene Blue in Pediatric Septic Shock: HUM00295080).
Participate in the Survey:
Or Scan the QR code:
Your expertise shapes current practice and identifies future pediatric critical care research questions.
Thank you for contributing to this important area of pediatric critical care research.
Comments